TARRYTOWN, N.Y., June 10, 2020 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it
has been named to The Civic 50 for the fourth consecutive year and
honored for the first time as the sector leader for healthcare. The
Civic 50 is an initiative of Points of Light, the world's largest
organization dedicated to volunteer service, and recognizes the
most community-minded companies in the United States.
"We are honored to be included among The Civic 50 and recognized
as a leading corporate citizen," said Leonard Schleifer, M.D., Ph.D., Founder,
President and Chief Executive Officer of Regeneron. "At Regeneron,
operating responsibly and in service of our communities is at the
heart of everything we do, from developing new medicines to
fostering a diverse and inclusive workplace, to donating time
and resources to the places where we work and live. Since our
founding, we have repeated the mantra of 'doing well by doing
good,' and we remain focused on living up to this promise."
"As we work to respond rapidly to the global COVID-19 pandemic
and the societal inequities it has compounded, we continue to use
the unique skills and expertise within our company to build
resiliency and equity in our communities," said Hala Mirza, Senior Vice President, Corporate
Communications and Citizenship at Regeneron. "This includes the
incredible efforts of our scientists to advance potential new
medicines for COVID-19 patients, bridging opportunity gaps for
students who are underrepresented in STEM fields and providing
support to communities in need."
The Civic 50 sets a national standard for superior corporate
citizenship and showcases how companies can use their time, skills
and resources to impact their communities. The Civic 50 honorees
are public and private companies with U.S. operations with revenues
of $1 billion or more, and are
selected based on four dimensions of their U.S. community
engagement program including investment, integration,
institutionalization and impact.
This honor recognizes Regeneron's integrated approach to
corporate responsibility and creating high-impact community
engagement programs and partnerships. In 2019, Regeneron invested
$19.2 million in non-profit
organizations to foster future generations of scientific leaders
and support the communities where it operates. In addition to its
10-year, $100 million commitment to
the Society for Science and the Public to support the Regeneron
Science Talent Search, Regeneron became the new title sponsor of
the International Science and Engineering Fair (ISEF), the world's
largest pre-college science and engineering competition. In
addition, Regeneron partnered with Cold Spring Harbor Laboratory to
open the Regeneron DNA Learning Center, a community learning lab
for middle and high school students. Regeneron also invests over
$3 million annually in science
education outreach and equity programs that specifically aim to
bridge opportunity gaps for students who historically have been
underrepresented in the sciences. Regeneron maximizes its
social and business impact by supporting volunteerism – in
2019, 59 percent of employees volunteered more than 27,800 hours,
time valued at $1.5 million.
In addition to Regeneron's research and development efforts to
combat COVID-19, the company has raised funds and mobilized
resources to support communities impacted by the pandemic. At the
height of the outbreak in New York
State, the Regeneron team donated $1
million worth of time and supplies to create 500,000 units
of viral transport media, a critical component of virus
testing kits that was in short supply in the state. The
company has also provided financial support for the Afya
Foundation, a medical supply recovery organization, and the Capital
Region Community Foundation's COVID-19 Response Fund, to address
the pressing needs of local communities during the pandemic. Also,
for the first time, Regeneron offered a Double Matching Gift
Campaign for employees, successfully raising $750,000 for the COVID-19 relief efforts of
several nonprofits operating in the communities where colleagues
work and live.
To learn more about The Civic 50, visit
http://www.Civic50.org.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading
biotechnology company that invents life-transforming medicines for
people with serious diseases. Founded and led for over 30 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to seven
FDA-approved treatments and numerous product candidates in
development, all of which were homegrown in our laboratories. Our
medicines and pipeline are designed to help patients with eye
diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, pain, infectious diseases
and rare diseases.
Regeneron believes that operating as a good corporate citizen is
crucial to delivering on our mission. We approach corporate
responsibility with three goals in mind: to improve the lives of
people with serious diseases, to foster a culture of
integrity and excellence and to build
sustainable communities. Regeneron is proud to be included on the
Dow Jones Sustainability World Index and the Civic 50 list of the
most "community-minded" companies in the
United States. Throughout the year, Regeneron empowers and
supports employees to give back through our volunteering, pro bono
and matching gift programs. Our most significant philanthropic
commitments are in the area of science education, including
the Regeneron Science Talent Search and the Regeneron
International Science and Engineering Fair (ISEF).
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
Regeneron
Contacts:
|
|
Media
Relations
|
Investor
Relations
|
Alexandra
Bowie
|
Vesna
Tosic
|
Tel.: +1 (914)
847-3407
|
Tel.: +1 (914)
847-5443
|
alexandra.bowie@regeneron.com
|
vesna.tosic@regeneron.com
|
View original
content:http://www.prnewswire.com/news-releases/regeneron-recognized-as-healthcare-sector-leader-on-the-civic-50-list-of-the-most-community-minded-companies-in-the-united-states-301073211.html
SOURCE Regeneron Pharmaceuticals, Inc.